The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 15, 2020
Filed:
Nov. 28, 2016
Applicant:
Boehringer Ingelheim Vetmedica Gmbh, Ingelheim am Rhein, DE;
Inventors:
Assignee:
Other;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/351 (2006.01); C07D 309/10 (2006.01); A61K 31/7034 (2006.01); C07H 15/207 (2006.01); A61K 9/02 (2006.01); A61K 9/00 (2006.01); A61K 31/7048 (2006.01); A61K 9/20 (2006.01); A61K 31/7056 (2006.01); A61K 31/70 (2006.01); A61K 31/7042 (2006.01); A61K 9/48 (2006.01); A61K 47/54 (2017.01);
U.S. Cl.
CPC ...
A61K 31/7034 (2013.01); A61K 9/0019 (2013.01); A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); A61K 9/02 (2013.01); A61K 9/20 (2013.01); A61K 9/2018 (2013.01); A61K 9/48 (2013.01); A61K 9/4866 (2013.01); A61K 31/351 (2013.01); A61K 31/70 (2013.01); A61K 31/7042 (2013.01); A61K 31/7048 (2013.01); A61K 31/7056 (2013.01); A61K 47/545 (2017.08); C07D 309/10 (2013.01); C07H 15/207 (2013.01);
Abstract
A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.